| 1 |
Ye J, Wu J, Liu B. Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. Biochim Biophys Acta Rev Cancer 2023;1878:188866. [PMID: 36842765 DOI: 10.1016/j.bbcan.2023.188866] [Reference Citation Analysis]
|
| 2 |
Shagufta, Ahmad I. Therapeutic significance of molecular hybrids for breast cancer research and treatment. RSC Med Chem 2023;14:218-38. [PMID: 36846377 DOI: 10.1039/d2md00356b] [Reference Citation Analysis]
|
| 3 |
Chen ZH, Xu RM, Zheng GH, Jin YZ, Li Y, Chen XY, Tian YS. Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility. Molecules 2023;28. [PMID: 36838705 DOI: 10.3390/molecules28041717] [Reference Citation Analysis]
|
| 4 |
Kochetkov KA, Gorunova ON, Bystrova NA. Biologically Oriented Hybrids of Indole and Hydantoin Derivatives. Molecules 2023;28. [PMID: 36677661 DOI: 10.3390/molecules28020602] [Reference Citation Analysis]
|
| 5 |
Krstulović L, Leventić M, Rastija V, Starčević K, Jirouš M, Janić I, Karnaš M, Lasić K, Bajić M, Glavaš-Obrovac L. Novel 7-Chloro-4-aminoquinoline-benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking. Molecules 2023;28. [PMID: 36677600 DOI: 10.3390/molecules28020540] [Reference Citation Analysis]
|
| 6 |
Maswadeh HM, Khan A, Alorainy MS, Al-Wabel NA, Demetzos C. Concomitant delivery of doxorubicin and cisplatin through liposome-based thermosensitive nanoparticles: perspective in the treatment of cancer in animal models. Am J Cancer Res 2023;13:379-93. [PMID: 36895979] [Reference Citation Analysis]
|
| 7 |
Samimi H, Tavakoli R, Fallah P, Naderi Sohi A, Amini Shirkouhi M, Naderi M, Haghpanah V. BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture. Cancer Cell Int 2022;22:388. [PMID: 36482411 DOI: 10.1186/s12935-022-02813-6] [Reference Citation Analysis]
|
| 8 |
Chalkha M, Nour H, Chebbac K, Nakkabi A, Bahsis L, Bakhouch M, Akhazzane M, Bourass M, Chtita S, Bin Jardan YA, Augustyniak M, Bourhia M, Aboul-Soud MAM, El Yazidi M. Synthesis, Characterization, DFT Mechanistic Study, Antimicrobial Activity, Molecular Modeling, and ADMET Properties of Novel Pyrazole-isoxazoline Hybrids. ACS Omega 2022;7:46731-44. [PMID: 36570248 DOI: 10.1021/acsomega.2c05788] [Reference Citation Analysis]
|
| 9 |
Bansode P, Pore D, Tayade S, Patil S, Choudhari P, Rashinkar G. Remarkable anticancer activity and molecular docking studies of ferrocene tethered pyrimidobenzothiazoles and pyrimidobenzimidazoles. Results in Chemistry 2022. [DOI: 10.1016/j.rechem.2022.100758] [Reference Citation Analysis]
|
| 10 |
Alshamari AK. Design and Synthesis of Novel 1,2,3-Triazole Levonorgestrel Derivatives via Click Chemistry. Anticancer Activity and Molecular Docking. Russ J Org Chem 2022;58:1878-1888. [DOI: 10.1134/s107042802212017x] [Reference Citation Analysis]
|
| 11 |
Kumar V, Haldar S, Ghosh S, Chauhan S, Sharma A, Dhankhar P, Kumar A, Jaiswal S, Saini S, Gupta S, Lahiri D, Roy P. Pterostilbene-isothiocyanate impedes RANK/TRAF6 interaction to inhibit osteoclastogenesis, promoting osteogenesis in vitro and alleviating glucocorticoid induced osteoporosis in rats. Biochem Pharmacol 2022;206:115284. [PMID: 36209841 DOI: 10.1016/j.bcp.2022.115284] [Reference Citation Analysis]
|
| 12 |
Höing A, Struth R, Beuck C, Rafieiolhosseini N, Hoffmann D, Stauber RH, Bayer P, Niemeyer J, Knauer SK. Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand. RSC Adv 2022;12:34176-84. [PMID: 36545626 DOI: 10.1039/d2ra06019a] [Reference Citation Analysis]
|
| 13 |
Dileep Kumar JS, Molotkov A, Carberry P, Chaly T, Neelamegam R, Mintz A. Radiosynthesis and evaluation of [11C]AG-488, a dual anti-angiogenetic and anti-tubulin PET ligand. Bioorg Med Chem Lett 2022;74:128941. [PMID: 35964845 DOI: 10.1016/j.bmcl.2022.128941] [Reference Citation Analysis]
|
| 14 |
Sflakidou E, Leonidis G, Foroglou E, Siokatas C, Sarli V. Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents. Molecules 2022;27:6632. [PMID: 36235168 DOI: 10.3390/molecules27196632] [Reference Citation Analysis]
|
| 15 |
Kaur P, Sharma P, Kumar V, Sahal D, Kumar R. Chitosan-supported FeCl3 catalyzed multicomponent synthesis of tetrahydroisoquinoline-indole hybrids with promising activity against chloroquine resistant Plasmodium falciparum. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.134406] [Reference Citation Analysis]
|
| 16 |
Khan A, Naaz F, Basit R, Das D, Bisht P, Shaikh M, Lone BA, Pokharel YR, Ahmed QN, Parveen S, Ali I, Singh SK, Chashoo G, Shafi S. 1,2,3-Triazole Tethered Hybrid Capsaicinoids as Antiproliferative Agents Active against Lung Cancer Cells (A549). ACS Omega. [DOI: 10.1021/acsomega.2c03325] [Reference Citation Analysis]
|
| 17 |
Liman W, Ait Lahcen N, Oubahmane M, Hdoufane I, Cherqaoui D, Daoud R, El Allali A. Hybrid Molecules as Potential Drugs for the Treatment of HIV: Design and Applications. Pharmaceuticals 2022;15:1092. [DOI: 10.3390/ph15091092] [Reference Citation Analysis]
|
| 18 |
Matore BW, Banjare P, Guria T, Roy PP, Singh J. Oxadiazole derivatives: Histone deacetylase inhibitors in anticancer therapy and drug discovery. European Journal of Medicinal Chemistry Reports 2022;5:100058. [DOI: 10.1016/j.ejmcr.2022.100058] [Reference Citation Analysis]
|
| 19 |
Fawzy NM, Ahmed KM, Abo-salem HM, Aly MS. Novel Furochromone Derivatives of Potential Anticancer Activity Targeting EGFR Tyrosine Kinase. Synthesis and Molecular Docking Study. Russ J Bioorg Chem. [DOI: 10.1134/s1068162022040082] [Reference Citation Analysis]
|
| 20 |
Fabitha K, Chandrakanth M, Pramod RN, Arya CG, Li Y, Banothu J. Recent Developments in the Synthesis of Indole‐Pyrazole Hybrids. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202201064] [Reference Citation Analysis]
|
| 21 |
Dhuguru J, Ghoneim OA. Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents. Molecules 2022;27:2294. [PMID: 35408693 DOI: 10.3390/molecules27072294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 22 |
Elgiushy HR, Mohamed SH, Taha H, Sawaf H, Hassan Z, Abou-taleb NA, El-labbad EM, Hassan AS, Abouzid KA, Hammad SF. Identification of a promising hit from a new series of pyrazolo[1,5-a]pyrimidine based compounds as a potential anticancer agent with potent CDK1 inhibitory and pro-apoptotic properties through a multistep in vitro assessment. Bioorganic Chemistry 2022;120:105646. [DOI: 10.1016/j.bioorg.2022.105646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Chen TC, da Fonseca CO, Levin D, Schönthal AH. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics 2021;13:2167. [PMID: 34959448 DOI: 10.3390/pharmaceutics13122167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Abourehab MAS, Alqahtani AM, Almalki FA, Zaher DM, Abdalla AN, Gouda AM, Beshr EAM. Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies. Molecules 2021;26:6582. [PMID: 34770990 DOI: 10.3390/molecules26216582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Abdalbari FH, Telleria CM. The gold complex auranofin: new perspectives for cancer therapy. Discov Onc 2021;12. [DOI: 10.1007/s12672-021-00439-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 26 |
Micale N, Molonia MS, Citarella A, Cimino F, Saija A, Cristani M, Speciale A. Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol. Molecules 2021;26:4665. [PMID: 34361819 DOI: 10.3390/molecules26154665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 27 |
Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem 2021;36:1702-14. [PMID: 34325588 DOI: 10.1080/14756366.2021.1945049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
